UCHL1 Expression in Colorectal Cancer: Clinicopathological Significance, Prognostic Value, and Implications for Immunotherapy Response
Open Access
- 27 August 2026
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 14 (9) , 1924
Abstract
Background/Objectives: Ubiquitin C-terminal hydrolase L1 (UCHL1) exhibits context-dependent roles in various cancers, but its clinical significance and biological functions specifically in colorectal cancer (CRC) remain incompletely understood. Methods: We systematically evaluated UCHL1 expression, clinicopathological associations, prognostic value, and immunological role in CRC using multiple public databases (TCGA, GTEx, UALCAN, GEPIA2, GSCA, and ENCORI) combined with immunohistochemical validation on a tissue microarray containing 80 paired CRC and adjacent normal tissues. Functional enrichment was assessed using ssGSEA, and immune cell infiltration was analyzed using the immunedeconv R package. The immunotherapy response was evaluated using the TIDE algorithm. Results: UCHL1 mRNA and protein levels were significantly downregulated in CRC tissues compared with normal tissues. Paradoxically, high UCHL1 expression was significantly associated with advanced T stage, N stage, TNM stage, and poor overall and disease-free survival. ssGSEA revealed positive associations with multiple aspects of oncogenic pathways, including tumor inflammation signature, tumor proliferation signature, epithelial–mesenchymal transition markers, extracellular matrix-related genes, angiogenesis, apoptosis, and G2M checkpoint regulation. Notably, UCHL1 expression was positively correlated with computationally estimated infiltration of macrophages, CD4+ T cells, and CD8+ T cells, and with elevated expression of immune checkpoint genes, as well as higher TIDE scores. These correlative findings suggest a potential association with immunotherapy-related pathways that warrants further investigation. Conclusions: UCHL1 is downregulated in CRC, but its elevated expression is associated with aggressive disease and poor prognosis. It is implicated in multiple oncogenic pathways and may contribute to an immunosuppressive tumor microenvironment, suggesting its potential as a candidate prognostic biomarker that warrants further functional investigation.Keywords
This publication has 40 references indexed in Scilit:
- Inhibition of UCH-L1 enhances immunotherapy efficacy in triple-negative breast cancer by stabilizing PD-L1European Journal of Pharmacology, 2025
- Identification of T cell dysfunction molecular subtypes and exploration of potential immunotherapy targets in BRAF V600E-mutant colorectal cancerDiscover Oncology, 2025
- Gut microbial metabolism in ferroptosis and colorectal cancerTrends in Cell Biology, 2024
- LncRNA ZFAS1 promotes invasion of medullary thyroid carcinoma by enhancing EPAS1 expression via miR‐214‐3p/UCHL1 axisJournal of Cell Communication and Signaling, 2024
- ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasionCell, 2024
- UCHL1 acts as a prognostic factor and promotes cancer stemness in cervical squamous cell carcinomaPathology - Research and Practice, 2023
- UCHL1 promotes cancer stemness in triple-negative breast cancerPathology - Research and Practice, 2022
- ggClusterNet: An R package for microbiome network analysis and modularity‐based multiple network layoutsiMeta, 2022
- CpG methylation of ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) and P53 mutation pattern in sporadic colorectal cancerTumor Biology, 2015
- Silencing of the UCHL1 gene in human colorectal and ovarian cancersInternational Journal of Cancer, 2006